Indeed, the first-in-class XPO1 inhibitor selinexor has shown activity in established cell line-based preclinical models of soft tissue sarcoma, including DDLPS [11–13], and a phase III randomized trial of selinexor versus placebo in patients with metastatic DDLPS (ClinicalTrials.gov identifier: NCT02606461) has recently completed the accrual [14]. The gene discussed is XPO1; the disease is dedifferentiated liposarcoma.